Medicare AdvantageCoverageMedium impact
MA08.152d, Nivolumab and relatlimab-rmbw (Opdualag™) for intravenous use
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Policy MA08.152d was reissued effective 03/04/2026 for Nivolumab and relatlimab-rmbw (Opdualag™) intravenous use. The provided information does not contain the specific policy content detailing coverage criteria, billing codes, prior authorization requirements, or other operational changes. Billing team must obtain the full policy text from the source URL to identify actionable changes.
Action Required
By 03/04/2026: Billing team must access the full policy text at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#medicare-advantage-ma08-152d-nivolumab-and-relatlimab-rmbw-o to extract specific coverage requirements, billing codes, prior authorization requirements, and documentation standards. Review policy for applicable HCPCS drug codes (likely J-codes for Nivolumab/relatlimab combination) and update billing system accordingly. Notify oncology providers of any changes to prior authorization procedures, medical necessity criteria, or documentation requirements for Opdualag™ administration. Failure to implement required changes by the effective date may result in claim denials.